AbbVie Inc. 2026: Revenue $16.99B, EPS $2.03— 10-Q Summary
AbbVie (ABBV) reported 2026-quarter net revenues of $16.99B and diluted EPS of $2.03, up from $15.42B and $0.52 a year earlier, with net earnings attributable to AbbVie rising to $3.61B. Results cited growth in Skyrizi, Rinvoq and other brands, while Humira sales fell about 36% amid biosimilar competition, per its 10-Q.
How this was made
The 30-second read
Why it matters
Traders can use the reported revenue/EPS and the stated brand and pipeline momentum to update short-term expectations and risk around upcoming regulatory submissions and Phase 3 readouts.
Market read
The article is primarily a fresh quarterly disclosure with specific brand and pipeline highlights that can influence earnings estimate revisions.
What to watch
The summary mentions a $650M upfront licensing payment and major manufacturing campus capex, but it does not quantify margin or cash-flow impact, which could matter for valuation and near-term estimates.
Background
This is a brief summary of AbbVie’s 2026-quarter 10-Q, highlighting reported financials, brand performance, and pipeline timing.
Ticker impact
AbbVie reported 2026-quarter net revenues of $16.99B and diluted EPS of $2.03, with brand growth offsetting Humira declines.
Moderately positive bias, with traders likely focusing on Skyrizi and Rinvoq momentum versus continued Humira erosion.
The article includes concrete reported figures (revenue, EPS, net income rebound) plus specific brand and pipeline readout expectations over the next 12 months, but it is a summary rather than full guidance detail.
Market effects
Biopharma investors may re-rate near-term demand durability for immunology and neuroscience franchises versus biosimilar pressure.
No explicit regional demand or regulatory shock is described beyond worldwide revenue growth.
Humira biosimilar competition and international expansion are global themes, but no country-specific catalyst is provided.
Counterpoint
Humira revenue is still falling sharply (about 36%), so the stock may be vulnerable if biosimilar share gains accelerate faster than offsets from other brands.
Key entities
- companyAbbVie Inc.
Reported 2026-quarter net revenues of $16.99B and diluted EPS of $2.03, with Skyrizi and Rinvoq strength offsetting Humira declines.
